黄芪、莪术配伍对人卵巢癌HO-8910原位移植瘤组织中MMP-2、FGF-2、BCL-2表达的影响  

Effect of Compatibility of Astragalus and Zedoary on Expressions of MMP-2,FGF-2 and BCL-2 in Orthotopic Transplantation Tumor Tissue of HO-8910 Ovarian Carcinoma in Situ

作　　者：时晓霞[1] 唐德才[1] 尹刚[1] 臧文华 张硕[1] SHI Xiaoxia;TANG Decai;YIN Gang;ZANG Wenhua;ZHANG Shuol(Jiangsu Collaborative Innovation Center of Ttraditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China;ZHANG Zhongjing College of Ttraditional Chinese Medicine, Nanyang Institute of Technology, Nanyang 473000, Henan, China)

机构地区：[1]南京中医药大学江苏省中医药防治肿瘤协同创新中心,江苏南京210023 [2]南阳理工学院张仲景国医国药学院,河南南阳473000

出　　处：《中华中医药学刊》2018年第6期1312-1315,I0008-I0010,共7页Chinese Archives of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(81073072,81373990);国家自然科学基金青年科学基金项目(81503267,81503270);江苏省高校自然科学基金项目(15KJB360003)

摘　　要：目的：观察黄芪、莪术配伍对人卵巢癌HO-8910原位移植瘤的抑瘤效果及瘤组织中MMP-2、FGF-2、BCL-2蛋白和基因表达的影响。方法：选取已建立荧光蛋白转染的HO-8910卵巢癌原位癌动物模型,分为模型组,阳性对照组（顺铂）,黄芪组,莪术组,黄芪、莪术配伍（按照2∶1）高、中、低剂量组,监测抑瘤效果。用免疫组化和Real time-PCR检测移植瘤组织中MMP-2、FGF-2、BCL-2蛋白和基因的表达情况。结果：阳性对照组,黄芪组,黄芪、莪术配伍高剂量组,黄芪、莪术配伍低剂量组平均肿瘤质量明显小于模型组（P〈0.05）;各组MMP-2、FGF-2、BCL-2蛋白表达与模型组相比无统计学差异（P〉0.05）;黄芪组,莪术组,黄芪、莪术配伍组高、中、低剂量组肿瘤组织中的MMP-2、FGF-2、BCL-2 mRNA表达明显低于模型组（P〈0.05）。结论：黄芪、莪术配伍使用在实验周期内对人卵巢癌HO-8910具有抑制作用（P〈0.05）,其作用机制可能与下调移植瘤中MMP-2、FGF-2、BCL-2基因表达相关。Objective： To observe the antitumor effect of Radix Astragali and Rhizoma Zedoariae of HO-8910 human ovarian cancer and the effect of expressions of MMP-2,FGF-2 and BCL-2 in orthotopic transplantation tumor. Methods：We selected the HO-8910 ovarian carcinoma in situ animal models which have been established fluorescent protein transfection,including model group,positive control group（ Cisplatin）,Astragalus group,Zedoary group,Astragalus-Zedoary turmeric compatibility groups（ on the basis of 2 ∶ 1） of low,middle and high dose. We dynamically measured the tumor inhibitory effect. The mRNA and protein expressions of MMP-2,FGF-2 and BCL-2 were deteced by Real time-PCR and immunohistochemical method. Results： The average tumor weights of the positive group,Astragalus group,Astragalus-Zedoary turmeric compatibility groups of low and high dose were significantly lower than that of the model group（ P〈0. 05）. The expressions of MMP-2,FGF-2 and BCL-2 in transplanted tumor tissue of each group showed no significant difference compared with those of the model control group（ P〉0. 05）. Comparing with the model group,the average expressions of MMP-2,FGF-2 and BCL-2 mRNA were significantly weakened in transplanted tumor tissue of the positive control group（ Cisplatin）,Astragalus group,Zedoary group,Astragalus-Zedoary turmeric compatibility groups of low,middle and high dose（ P〈0. 05）. Conclusion： In the experimental period,the antitumor effect of Astragalus and zedoary turmeric on human ovarian cancer HO-8910 was obvious（ P〈0. 05）. The action mechanism may be associated with the down-regulation of expressions of MMP-2,FGF-2 and BCL-2 mRNA.

关 键 词：黄芪 莪术 卵巢癌 MMP-2 FGF-2 BCL-2 

分 类 号：R285.5[医药卫生—中药学]